OncLive TV

Ahmad A. Tarhini, MD, PhD, discusses findings from the ECOG-ACRIN EA6194 trial of pembrolizumab plus vidutolimod in resectable melanoma.

Lyudmila A. Bazhenova, MD, discusses ways that sunvozertinib expands the treatment paradigm for EGFR-mutated metastatic non–small cell lung cancer.

Rachel Riechelmann, MD, PhD, discusses clinical guidance for the management of refractory carcinoid syndrome in functional GI neuroendocrine tumors.

Shahzad Raza, MD, shares preliminary data from the NEXICART-2 trial of NXC-201 in relapsed/refractory light chain amyloidosis.

Ronan J. Kelly, MD, expanded on data from the phase 3 CheckMate 577 study of adjuvant nivolumab following CRT in resected esophageal and GEJ cancer.

Chinmay Jani, MD, discusses the rate of inclusion of patient-reported outcome end points in clinical trials of patients with lung cancer.

Ravindra Uppaluri, MD, PhD, discusses the FDA approval of pembrolizumab in the neoadjuvant and adjuvant setting for resectable, locally advanced HNSCC.

Bhavana Pothuri, MD, discusses remaining unmet needs for patients with recurrent/advanced endometrial cancer.

Juan Vasquez, MD, discussed unmet needs for patients with pediatric rhabdomyosarcoma that investigations of NAMPT inhibition may address.

John O. Mascarenhas, MD, discusses the safety profile of imetelstat plus ruxolitinib in patients with higher-risk myelofibrosis.

Premal H. Thaker, MD, MS, discusses the safety of intraperitoneal administration of IMNN-001 plus neoadjuvant chemotherapy in epithelial ovarian cancer.

Noha Soror, MD, discussed data from an analysis of patient-reported outcomes in from hospitalized patients with cancer.

Katherine C. Ansley, MD, discusses the importance of the phase 3 INAVO120 trial in PIK3CA-mutated, hormone receptor–positive, HER2-negative breast cancer.

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Zev A. Wainberg, MD, MSc, discusses data from the EDGE-Gastric trial of domvanalimab plus zimberelimab and FOLFOX in first-line, metastatic gastric cancer.

Ruby Arora, MD, discusses findings from a SEER database analysis of mantle cell lymphoma incidence rates from 2000 to 2021.

Lydia Scarfò, MD, explains the rationale for evaluating the BTK degrader BGB-16673 for patients with relapsed/refractory CLL.

Jason A. Mouabbi, MD, discusses the importance of achieving consensus for integrating CompassHER2-pCR data into early-stage HER2+ breast cancer management.

Alexey Danilov, MD, PhD, discussed how chemotherapy-free regimens have influenced treatment decision-making for patients with mantle cell lymphoma.

Nagi S. El-Saghir, MD, FACP, FASCO, discusses the clinical implications of the phase 2 RIGHT Choice trial.

Kohei Shitara, MD, details the mechanisms of action of the investigational therapies domvanalimab and zimberelimab for gastrointestinal cancer.

Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the mantle cell lymphoma treatment paradigm.

Balazs Halmos, MD, discusses the differences in presentation and available treatments between neuroendocrine tumors and neuroendocrine carcinomas.

R. Lor Randall, MD, FACS discusses the evolving role of surgical management in patients with low-grade chondrosarcoma.

Misako Nagasaka, MD, PhD, discussed the clinical significance of the FDA approval of taletrectinib in ROS1-positive NSCLC.

Francesca Palandri, MD, shares SVR35 rates with momelotinib vs ruxolitinib across patient subgroups in the anemic subpopulation of SIMPLIFY-1.

Michele Reni, MD, discusses the efficacy of pre-operative PAXG compared with modified FOLFIRINOX in stage I to III PDAC.

Douglas B. Johnson, MD, MSCI, highlighted avenues for improving immunotherapy use in melanoma during Cancer Immunotherapy Awareness Month.

Justin Moser, MD, discusses the design and implications of the SUPRAME trial investigating IMA203 in pretreated advanced cutaneous melanoma.

Claudine Isaacs, MD, discusses how to integrate data from the phase 3 DESTINY-Breast09 trial into the HER2-positive metastatic breast cancer paradigm.